Qaytarish

МАR-тест (антитела Ig G на поверхности сперматозоидов)

Kod:6031

Tahlil ma'lumotlari

Tadqiqot usuli

—

Kutilayotgan natija topshirish vaqti

1 kun

Maxsus tayyorlik

  • Maintain ejaculatory abstinence for at least 2 days and no more than 7 days; use the same abstinence interval for repeat testing.
  • Avoid alcohol completely for 6–7 days before collection.
  • With clinician approval, hold nonessential medications for 24 hours before the test.
  • Avoid heat exposure for 7 days prior, including sauna/steam baths, occupational hyperthermia, and febrile illness.
  • Do not undergo physiotherapy or radiologic examinations within 72 hours before collection.
  • Avoid intoxication from tobacco, recreational drugs, occupational exposures, or toxic agents; if intoxication occurs, postpone testing for 5–10 days.
  • After an acute febrile illness (including respiratory infections), wait 7–10 days before providing a specimen.
  • Wait 3–4 days after prostate massage before collection.
  • After treatment of inflammatory genitourinary conditions, wait 2 weeks before testing.
  • On the day before collection, avoid strenuous exercise and acute psychosocial stress.
  • Empty the bladder immediately before specimen collection.
  • Do not use condoms or lubricants, including saliva, to collect the ejaculate.
  • Wash hands and external genitalia before masturbation.
  • Collect the entire ejaculate.

Qanday foydalanish

MAR-testi bilan birgalikdagi sperma tahlili (aralash antiglobulin reaksiyasi, SpermMAR) ejakulyatning odatiy parametrlarini hamda spermatozoid yuzasiga bog'langan IgA va IgG sinfidagi antisperm antitanachalarni baholaydi. Ushbu birlashtirilgan baholash erkaklarning fertillik salohiyatini baholashni qo'llab-quvvatlaydi va subfertillikka immunologik omillarni aniqlaydi. U homiladorlikka erishishning buzilishi sabablari aniqlanishi, yordamchi reproduktiv texnologiyalarni (shu jumladan sun'iy urug'lantirish) tanlashni asoslash, prostatit kabi reproduktiv yo'l kasalliklarida differensial diagnostikaga yordam berish hamda terapiyadan keyingi javobni hujjatlashtirish uchun qo'llaniladi. Shuningdek, test vazektomiya samaradorligini monitoring qilish va davolashdan keyingi o'zgarishlarni kuzatish uchun ishlatiladi.

Cheklovlar

Taxminan 1 ta juftlikdan 15 tasidan 1 tasida homiladorlikka erishishda qiyinchilik kuzatiladi va holatlarning taxminan 20–25% ida erkak omili ishtirok etadi. Sperma anomaliyalari azoospermiyadan tortib spermatozoidlar soni yoki sifatining kamayishigacha bo'lgan spektrni qamrab oladi. Shu sababli, sperma tahlili erkak fertilligi bahosining asosi hisoblanadi, uni MAR-test bilan birlashtirish esa antisperm antitanachalarni aniqlash orqali immunologik komponentni aniqlashga yordam beradi. Normal urug' suyuqligi fiziologiyasi moyaklar, urug' pufakchalari va prostata bezining uyg'un faoliyatiga bog'liq. Urug' pufakchalari ejakulyat hajmining asosiy qismini (taxminan 45–80%) ta'minlaydi. Urug' suyuqligi ishqoriy bo'lib, qin muhitining kislotali ta'sirini buferlaydi va spermatozoidlar harakatlanishi uchun yoqilg'i bo'ladigan fruktozani o'z ichiga oladi. Umumiy hajmning atigi taxminan 1% ini spermatozoidlar va moyaklardan keladigan moyak suyuqligi tashkil etadi. Erkak bepushtligi spermatozoidlar ishlab chiqarilishi yoki funksiyasini buzadigan turli etiologiyalardan kelib chiqadi. Varikotsele holatlarning taxminan 40% ini tashkil etadi va odatda jarrohlik yo'li bilan davolanadi. Moyaklarning yallig'lanishi taxminan 10% ni tashkil etadi va bu holat yomon sifatli o'sma, epidemik parotit kabi infeksiyalar, Klaynfelter sindromi kabi genetik buzilishlar, shikastlanish yoki avvalgi nurlanish va ximiyoterapiyadan kelib chiqishi mumkin. Gidrotsele qo'shimcha ~10% ni tashkil etadi. Spermatogenezni buzadigan endokrin kasalliklar taxminan 9% ni tashkil etadi va ko'pincha gipofiz yoki buyrak usti bezlarining gipoplaziyasi yoki giperoestrogenemiya bilan bog'liq bo'ladi. Ejakulyator yo'lining obstruksiyasi holatlarning taxminan 5% iga sabab bo'ladi. Antisperm avtoantitanachalar bepushtlik bilan og'rigan erkaklarning taxminan 1–2% ida aniqlanadi, bu esa MAR-testni an'anaviy sperma tahliliga qo'shimcha sifatida ahamiyatini ta'kidlaydi.

Referens oraliq—
Ko'rsatmalarEvaluation of a male partner for suspected infertility or subfertility, Preconception assessment when reduced fecundity is a concern, including a history of mumps (epididymo‑orchitis), Workup prior to assisted reproductive technologies, such as in vitro fertilization or intrauterine/artificial insemination, Post‑vasectomy follow‑up to confirm contraceptive effectiveness, Postoperative assessment after procedures that may alter spermatogenesis (for example, varicocelectomy), Assessment when a urologic disorder is suspected, Evaluation after conditions associated with disruption of the blood–testis barrier, including prior infections, varicocele, cryptorchidism, trauma, surgery, or malignancy

Namunangiz talablari

NamunangizSperma
ContainerSteril idish